Het opsporen van familieleden met een hogere kans op kanker door het vinden van erfelijke varianten bij mannen met uitgezaaide prostaatkanker in de reguliere gezondheidszorg

The use of germline genetic tests in patients with prostate cancer is increasing. International guidelines recommend to consider a germline genetic test in patients with metastatic prostate cancer. To improve access to genetic testing in patients with metastatic prostate cancer, mainstreaming of germline genetic testing is implemented in multiple hospitals in the Netherlands. In the mainstreaming pathway urologists, oncologists and nurse specialists discuss and order germline genetic tests themselves in patients with stage TxNxM1 prostate cancer. These healthcare professionals will be trained with the use of an online training module. The online training module can be completed in one hour and describes background knowledge and key information for counseling patients with metastatic prostate cancer. The aim of this study is to assess the experiences of patients and non-genetic healthcare professionals with this pathway with the use of questionnaires. Besides this, the efficacy of the mainstreaming pathway will be determined, based on the uptake of germline genetic testing, the diagnostic yield and the number of families with a germline variant that can yearly be identified with this pathway.

Mainstreaming of germline genetic tests in regular healthcare is feasible for healthcare professionals and acceptable for both patients and healthcare professionals

Patients: T0 directly after healthcare professional discussed and ordered germline genetic test. T1 4 weeks after receiving genetic test result. T2 6 months after receiving genetic test result. Healthcare professionals: T0 before attending online training module. T1 3 months after attending online training module. T2 9 months after attending online training module.